Erlinda Maria Gordon

机构：Sarcoma Oncology Center · ORCID：0000-0003-2599-7188

发表论文 199 篇 · 总被引 4038 次 · h-index 38

代表论文

• Phase II Trial of nab- Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update (2024 · Journal of Clinical Oncology · 被引 51)
• SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma (2023 · Cancers · 被引 38)
• Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311) (2023 · Frontiers in Oncology · 被引 20)
• A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab -Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway (2023 · Anticancer Research · 被引 11)
• Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis. (2024 · Journal of Clinical Oncology · 被引 6)
• Gene and Cell Therapy for Sarcomas: A Review (2025 · Cancers · 被引 4)